Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846541 | 0.97 | SMN1; SMN2 (0.35) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL4846388 | 0.85 | KDM4E (0.31) | KDM4EMAPTPOLBNPSR1ALDH1A1 | |
| SCHEMBL4901945 | 0.82 | AKR1B1 (0.32) | SMN1; SMN2GAA | |
| SCHEMBL4847587 | 0.82 | AKR1B1 (0.32) | SMN1; SMN2GAA | |
| SCHEMBL6320203 | 0.77 | RAB9A (0.37) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL13681624 | 0.71 | GRM5 (0.38) | KDM4EMAPTPOLBNPSR1ALDH1A1 | |
| SCHEMBL7712031 | 0.71 | NPSR1 (0.38) | KDM4EMAPTPOLBNPSR1ALDH1A1 | |
| SCHEMBL2209439 | 0.71 | NPSR1 (0.45) | NPC1RAB9AKDM4EMAPTPOLB | |
| SCHEMBL7592861 | 0.71 | NPC1 (0.37) | SMN1; SMN2NPC1RAB9AMAPTPOLB | |
| SCHEMBL7164438 | 0.71 | NPSR1 (0.39) | SMN1; SMN2GAANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396947-B2 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | SMN1; SMN2 4626/4885GAA 904/4885NPC1 2599/4885 |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | SMN1; SMN2 4626/4885GAA 904/4885NPC1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.